Chemokine/Chemokine Receptor Indications in extramedullary leukaemia of the skin in childhood AML: differential roles for CCR2, CCR5, CXCR4 and CXCR7

Autor: R. Maarten Egeler, Maarten J. D. van Tol, T Revesz, Claudia M.J.M. Faaij, Astrid G. S. van Halteren, Elisabeth R. van Wering, Christian M. Zwaan, Melania Balzarolo, Annemieke Willemze, Cornelis P. Tensen, Gertjan J.L. Kaspers, Maarten H. Vermeer, Nicola E. Annels, Jaak M. Vossen, Colin Story, Manja Hoogeboom
Přispěvatelé: Immunology, Pediatrics, Pediatric surgery, CCA - Innovative therapy
Rok vydání: 2010
Předmět:
Zdroj: Pediatric Blood & Cancer, 55, 344-348. Wiley-Liss Inc.
Pediatric Blood & Cancer, 55(2), 344-348
Pediatric Blood and Cancer, 55(2), 344-348. Wiley-Liss Inc.
Pediatric Blood & Cancer
Faaij, C M J M, Willemze, A J, Revesz, T, Balzarolo, M, Tensen, C P, Hoogeboom, M, Vermeer, M H, van Wering, E R, Zwaan, C M, Story, C, van Halteren, A G S, Kaspers, G J L, Vossen, J M, Egeler, R M, van Tol, M J D & Annels, N E 2010, ' Chemokine/Chemokine Receptor Interactions in Extramedullary Leukaemia of the Skin in Childhood AML: Differential Roles for CCR2, CCR5, CXCR4 and CXCR7 ', Pediatric Blood and Cancer, vol. 55, no. 2, pp. 344-348 . https://doi.org/10.1002/pbc.22500
ISSN: 1545-5009
DOI: 10.1002/pbc.22500
Popis: Chemokine receptor/ligand interactions orchestrate the migration of cells to peripheral tissues such as the skin. We analysed chemokine receptor expression by acute myeloid leukaemic (AML) cells present in peripheral blood (n = 7), bone marrow (n = 6), or skin (n = 11) obtained from 15 paediatric AML patients with skin involvement and in 10 AML patients without skin involvement. High percentages of circulating CCR2(pos) AML cells were only detected in patients with extramedullary disease. Skin-residing AML cells displayed a different set of receptors in situ, namely: CCR5, CXCR4, CXCR7 and CX3CR1. These results suggest the involvement of different chemokine/chemokine receptor interactions in homing and retention of AML blasts in the skin. Pediatr Blood Cancer 2010;55:344-348. (C) 2010 Wiley-Liss, Inc.
Databáze: OpenAIRE